Constanze Schneider

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

Constanze Schneider, Thomas Oellerich, Hanna‐Mari Baldauf et al. · Nature Medicine · 2016 · 185 citations

Medicine, Oncology, Pharmacology +14

The proteogenomic subtypes of acute myeloid leukemia

Ashok Kumar Jayavelu, Sebastian Wolf, Florian Buettner et al. · Cancer Cell · 2022 · 147 citations · Full text

Life Sciences, Molecular Biology, Oncology +14

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Thomas Oellerich, Constanze Schneider, Dominique Thomas et al. · Nature Communications · 2019 · 84 citations · Full text

Medicine, Oncology, Pharmacology +15

The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1

Kirsten M. Knecht, Olga Buzovetsky, Constanze Schneider et al. · Proceedings of the National Academy of Sciences · 2018 · 62 citations · Full text

Medicine, Oncology, Pharmacology +15

Diagnostic relevance of metastatic renal cell carcinoma in the head and neck: An evaluation of 22 cases in 671 patients

A. Lieder, Thomas Guenzel, Steffen Lebentrau et al. · International braz j urol · 2017 · 52 citations · Full text

Medicine, Oncology, Genitourinary Oncology +16